Roche Is Willing to Pay a Pretty Penny for the Rest of Foundation Medicine

Roche already owns a majority stake in Foundation Medicine, but now the Swiss company wants to buy the rest of the genomic diagnostics company, and it is willing to pay a pretty penny to do so. Roche agreed to pay $137 a share to buy the rest of Cambridge, MA-based Foundation Medicine, a $2.4 billion transaction that values the company at $5.3 billion. The offer price represents a 29% premium over Foundation Medicine's closing stock price Monday. The deal is expected to close during the second half of the year. The deal marks a turning point in Roche's relationship with Foundation Medicine, which dates back to January 2015 when Roche invested roughly $1.03 billion to acquire a majority interest in Foundation Medicine. The partnership included a broad R&D collaboration to accelerate Foundation Medicine's new product development initiatives, optimize treatments for cancer patients, and better design and understand the results of clinical trials based on molecular information, as well as a commercial collaboration aimed at expanding the global sales efforts for the company's products. Foundation Medicine develops genomic profiling assays designed to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trials. Roche said Foundation Medicine will continue to operate as a separate and autonomous legal entity. In December 2017, Foundation Medicine scored FDA approval for a first-of-its-kind ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news

Related Links:

This article provides an overview of AZD1775, based on English peer-reviewed articles on MEDLINE. The authors highlight the data from the published preclinical and clinical studies. Expert opinion: A majority of the current clinical trials focus on AZD1775 combined with chemotherapy or radiation. Treatment with AZD1775 was tolerated and antitumor activity has been observed, especially in patients with advanced malignancies harboring G1 checkpoint aberrations and/or DNA damage repair defects. Thus, identification of the molecular subtypes that benefit most from the treatment with AZD1775 alone or in combination may provide ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
The immunologic landscape of tumors has been continuously unveiled, providing a new look at the interactions between cancer cells and the immune system. Emerging tumor cells are constantly eliminated by the immune system, but some cells establish a long-term equilibrium phase leading to tumor immunoediting and, eventually, evasion. During this process, tumor cells tend to acquire more mutations. Bearing a high mutation burden leads to a greater number of neoantigens with the potential to initiate an immune response. Although many tumors evoke an immune response, tumor clearance by the immune system does not occur due to a ...
Source: Clinics - Category: General Medicine Source Type: research
AbstractIn this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting ( ‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. Here, we define ‘Microbial Therapy’ to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have sim ilar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Authors: Rybarczyk-Kasiuchnicz A, Ramlau R Abstract Lung cancer is the main cause of cancer-related deaths in Poland. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a new group of agents for non-small-cell lung cancer (NSCLC) patients. Determining the predictive value of activating mutations in the EGFR and ROS-1 genes and ALK rearrangement in non-small-cell lung cancer has enabled the identification of patients likely to achieve true clinical benefits. EGFR-TKIs may produce objective response in more than 60% of patients and prolong progression-free survival to 10 months in mutation-posit...
Source: Polish Journal of Cardio-Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Kardiochir Torakochirurgia Pol Source Type: research
As immunotherapies continue to emerge as a standard component of treatment for a variety of cancers, the imperative for testing these in combination with other standard cancer therapies grows. Radiation therapy may be a particularly well-suited partner for many immunotherapies. By modulating immune tolerance and functional immunogenicity at a targeted tumor site, radiation therapy may serve as a method of in situ tumor vaccination. In situ tumor vaccination is a therapeutic strategy that seeks to convert a patient's own tumor into a nidus for enhanced presentation of tumor-specific antigens in a way that will stimulate and...
Source: Brachytherapy - Category: Cancer & Oncology Authors: Tags: Review Article Source Type: research
Conclusion The importance of pharmacovigilance in oncology must be highlighted with every effort, to improve safety and offer cancer patients every possible help to improve their quality of life during such a critical period of their lives.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: FRα is overexpressed in high-grade TNBC and post-chemotherapy residual tumors. It participates in cancer cell signaling and presents a promising target for therapeutic strategies such as antibody-drug conjugates, or passive immunotherapy priming Fc-mediated anti-tumor immune cell responses. PMID: 30068707 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Neurologic complications of systemic cancer therapy encompass a range of symptoms that can affect the central nervous system (CNS), peripheral nervous system (PNS), or both. Their incidence will likely increase as novel agents, such as targeted therapy and immunotherapy, become incorporated into standard treatment regimens, and the number of long-term cancer survivors rises. Recognizing the common adverse effects of treatment is important to avoid misdiagnosis of cancer recurrence in the nervous system or paraneoplastic disease. Ongoing has focused on identifying patient-specific risk factors that predispose to drug toxici...
Source: Neurologic Clinics - Category: Neurology Authors: Source Type: research
Nephrotoxicity from cancer therapies is common and increasingly encountered in clinical practice, such that the subfield of "onco-nephrology" has emerged. Conventional chemotherapeutic drugs and novel agents targeting specific genes/proteins are effective cancer therapies but suffer from a number of adverse kidney effects. An effective avenue of cancer treatment is immunotherapy, which uses drugs that augment immune system–mediated recognition and targeting of tumor cells. As such, leveraging the immune system to target malignant cells represents an important modality in eradicating cancer. IFN and high-dos...
Source: Journal of the American Society of Nephrology : JASN - Category: Urology & Nephrology Authors: Tags: Review Source Type: research
AbstractInhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immune evasion. One mechanism inhibiting the innate response is the presence of the macrophage inhibitory molecule, signal regulatory protein- α (SIRPα), on tumor-associated macrophages (TAMs) and its cognate ligand cluster of differentiation 47 (CD47) on tumor cells in the tumor microenvironment. On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potential inhibitory receptors that possess ne w functions beyond T cell exhaustion in this review. As more and more imm...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Immunotherapy | Legislation | Medical Devices | Switzerland Health